Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Illumina reported revenue of $1.09 billion for Q1 2023, marking a 1% increase from Q4 2022 but a 11% decrease from Q1 2022. GAAP diluted EPS was $0.02, down from $0.55 a year prior. Non-GAAP diluted EPS was $0.08, compared to $1.07 in Q1 2022. The company reiterated its 2023 revenue guidance of 7% to 10% growth, with Core Illumina expected to grow by 6% to 9% and GRAIL revenue projected between $90 million and $110 million. Illumina anticipates a GAAP diluted loss per share in the range of $(0.28) to $(0.03), while maintaining non-GAAP EPS guidance of $1.25 to $1.50. The company is committed to achieving non-GAAP operating margins of 25% in 2024 and 27% in 2025, also announcing plans for over $100 million in annualized cost savings.